Jim Cramer's Mad Money Review

Just so you know, I just issued an alert. ... You should buy it here," he said of the cosponsors of Vytorin, which made headlines today after the Food and Drug Administration said it would issue early communication on the drug. He's reminded of Bausch and Lomb, Bristol-Myers Squibb (BMY) and other pharmaceutical companies that experienced exaggerated stock-price dives on bad news. Those situations, Cramer said, represented buying opportunities.
"The headline risk in drugs is also far worse," Cramer said. "This is what happens with drug stocks. Everyone panics at the same time. They get knocked all the way down."
"This is just unbelievable to me," Cramer added, saying that to cut shares of Schering-Plough so much, investors would have to believe the FDA was going to pull Vytorin.
Cramer continued, "I would buy Merck too. ... This is a classic headline overreaction."
Cramer concluded by saying he prefers Thornburg Mortgage (TMA) and Toll Brothers (TOL) to Fannie Mae (FNM) and Freddie Mac (FRE). "I just think that they're not investible. ... I didn't like them ... yesterday."
Published By TheStreet.com

Labels: BMY, FNM, FRE, Jim Cramer, Stop Trading, TMA, TOL

The Dow closed down 211 points and the Nasdaq finishing down 34. The S&P 500 has now given up all of its gains on the year. Najarian continues to like the four horseman names like Apple (AAPL), Google (GOOG) and Research In Motion (RIMM) which showed strength on Wednesday. Adami recommended getting long General Motors (GM) right here with a specific stop price in mind. Finerman found it strange that Fannie Mae (FNM) went up Wednesday. Crude oil came close to $100 on Wednesday, but fell just short and finished the day at $97.19. Gartman feels the stock market is behaving horribly and he is short names like Harley-Davidson (HOG), Tiffany (TIF) and Coach (COH) and long Microsoft (MSFT)and Apple (AAPL). Gartman's favorite position right now is short Cummins (CMI).
CNBC Pharmaceuticals Reporter Mike Huckman joined the show to discuss his take on big pharma stocks. Huckman explained that Pfizer (PFE) is having issues with safety concerns on a stop smoking drug, falling Lipitor sales and generic competition. Huckman also mentioned that Merck (MRK), Eli Lilly (LLY) and Bristol Myers (BMY) were all down on Wednesday. Finerman likes Johnson & Johnson (JNJ).
Investors tend to sell their biggest losers towards the end of the year to reduce the tax hit they take from their winners. Some of the names at 52-week lows are Citigroup (C), Pfizer (PFE), Merck (MRK), J.C. Penny (JCP), Capital One Financial (COF), Advanced Micro Devices (AMD) and AIG (AIG).
Word on the Street
Macke recommended buying The Gap (GPS) on dips. Finerman likes Limited (LTD) on valuation. Adami suggested buying Citi Trends (CTRN) ahead of earnings for Monday. Najarian likes Target (TGT) for its valuation in retail.
Deere & Company (DE) traded up 5% after profits rose 52%.
Najarian suggests looking at Agco (AG)
Najarian noted strong call options trading activity on Tibco Software (TIBX).
Pops & Drops
Pops - Google (GOOG) traded up 2%
U.S. Steel (X) traded up 5% also bucking the down trend in the market.
Drops - Tesoro (TSO) fell 3%
American International Group (AIG) fell 6%.
Circuit City (CC) fell 6% after a JPMorgan analyst downgraded the stock.
Jamba Juice (JMBA) plunged 30%
Final Trade
Macke says don't buy stocks if you don't have to and Adami and Finerman just gave thanks in the holiday spirit.
Najarian likes Apple (AAPL) and he thinks the stock will explode into January.

Labels: AAPL, BMY, CMI, CNBC, CNBC's Fast Money, COF, COH, Fast Money Recap, FNM, GM, GOOG, HOG, LLY, LTD, MRK, MSFT, pfe, RIMM, TGT, TIF

Accenture (NYSE:ACN - News) beat earnings late Tuesday with $0.47 EPS over an expected $0.42 EPS. ACN's PowerRating is 6.
Arrow International (NasdaqGS:ARRO - News) missed earnings Tuesday afternoon; analysts were looking for $0.36 EPS, but the company announced $0.32 EPS. ARRO's PowerRating is 6.
It was reported that Sanofi-Aventis (NYSE:SNY - News) could be eying a partnership with Bristol-Meyers Squibb (NYSE:BMY - News). SNY's PowerRating is 4, and BMY's PowerRating is 5.
Paychex (NasdaqGS:PAYX - News), Resources Connect (NasdaqGS:RECN - News) and Sonic (NasdaqGS:SONC - News) all report on Wednesday after the market closes, so watch for heightened price action and volume ahead of the bell. PAYX's PowerRating is 6, RECN's PowerRating is 4 and SONC's PowerRating is 4.
PowerRatings are courtesy of PowerRatings.net

Labels: ACN, ARRO, BMY, Hot Stocks, PAYX, RECN, SNY, SONC

Bullish calls:
Saks (NYSE: SKS - News): 'The company is en fuego. This is one of my favorite situations ... SKS is going up - I think - 4 or 5 more points.'Sprint Nextel (NYSE: S - News): 'I was impressed about that last quarter. I had been very negative about S ... They blew away the numbers. I think S is now a buy, buy, buy, particularly under $20. That stock can go much higher.'Transocean (NYSE: RIG - News): 'Take a look at the rates that RIG is now getting.'Halliburton (NYSE: HAL - News): 'HAL is on the move. I have said this is going to be one of my best stocks of 2007, and I am reiterating a triple buy. Buy, buy, buy!'Logitech International (NasdaqGS: LOGI): ' I'm actually surprised this stock isn't doing better. They make the fabulous peripherals we all use. They make great mice. They did miss the quarter. I think the stock is a buy. I'm not backing away from LOGI.'Dean Foods (NYSE: DF - News): 'That company is all about returning money to shareholders. That special dividend plan is brilliant. I really want to plug these guys.'Genzyme (NasdaqGS: GENZ): 'I think you've got to buy this company. I think that people are very worried about congressional action against biotech. That's not going to happen. GENZ's good.'Gilead (NasdaqGS: GILD): 'GILD's good.'Celgene (NasdaqGS: CELG): 'CELG's good. 'Walter Industries (NYSE: WLT - News): It shouldn't have been hammered. All aboard! ... There's a lot of value there, if they choose to bring it out.'Baxter International (NYSE: BAX - News): 'BAX is the one that is operating on every single cylinder. I applaud BAX for what it's done. That stock has been at or near the 52-week high list for about a half a dozen years. BAX's a winner!'Bard (NYSE: BCR - News)MasterCard (NYSE: MA - News): ' This is an 'among the rubble' stock that came down during the selloff that I want to tell you right now... you need to buy more MA! I would pull the trigger multiple times. That's how much I like MA here. All aboard!'Emerson Electric (NYSE: EMR - News): 'Right here, it's got a 2.5% yield. It's one of the best-run manufacturers in the country ... It's growing at almost 12%. It sells at 16x earnings.'Parker Hannifin (NYSE: PH - News)Illinois Tool Works (NYSE: ITW - News)Vail Resorts (NYSE: MTN - News): 'I'll tell you, it's had a big run ... You know what, that's a good stock. On a pullback, I would have to pull the trigger. Buy, buy, buy!'Regal Entertainment (NYSE: RGC - News): 'You want to be there! These companies - these cinema companies are good - it's got a nice dividend. I think that this group was bad before. They've fixed their balance sheets. You should pull the trigger. I would own RGC.'Ceradyne (NasdaqGS: CRDN): 'To tell you the truth, I'd rather be in CRDN.'Union Pacific (NYSE: UNP - News): 'Oh man, that stock is rocking ... I say it goes to $120.'Goldman Sachs (NYSE: GS - News)
Bearish calls:
Global Industries (NasdaqGS: GLBL): ' I would swap out of GLBL and go into GSF, RIG or HAL.'RF Micro Devices (NasdaqGS: RFMD): 'Yeah, this is one of those little stocks that has had a nice move ... I think that you are too late, but these always come back again. I would sell, sell, sell, and when it comes in, back to $6 - buy, buy, buy!'Acorda Therapeutics (NasdaqGM: ACOR): 'I've got to tell you, this is a very speculative stock. I'm reluctant to recommend it, with a lot of the great biotech stocks trading down so badly ... Don't buy, don't buy.'Research In Motion (NasdaqGS: RIMM): 'I was not happy with Jim Balsillie [ co-CEO] with the options stuff... I expected more of Jim than that. He's one of my favorite executives. I do think that RIMM is good place to be ... Don't buy, don't buy. It's just too, too hard.'ExpressJet (NYSE: XJT - News): ' Look, XJT is frankly a don't buy. I don't want to go there. Don't buy, don't buy.'Bristol-Myers (NYSE: BMY - News): ' Sunshine, I've got to tell you something... I think that BMY is just okay right here. Don't buy, don't buy. It's had a very big move. I liked it much lower ... Sell, sell, sell!'Pioneer Drilling (AMEX: PDC - News): 'You cannot go with this land drilling! ... Sell, sell, sell, sell, sell, sell. It won't work!'Take-Two Interactive (NasdaqGS: TTWO): 'I have been mad at myself. Yesterday, I looked at Steve Cohen's position in DE Shaw, and said to myself, 'These guys are going to replace management at TTWO. Maybe that's a reason to buy it.' That was a mistake. When I look at the core business, I don't know if there's anything there. I think I was too aggressive with TTWO ... I think Steve Cohen is a terrific guy. I totally respect his work. I think he might be wrong about TTWO.'Jefferies (NYSE: JEF - News): 'No, no. Missed the quarter. Missed the quarter.'Force Protection (NasdaqCM: FRPT) 'To tell you the truth, I'd rather be in CRDN.'
Published By SeekingAlpha

Labels: BAX, BCR, BMY, DF, EMR, GENZ, GILD, GS, HAL, JEF, Lightning Round, LOGI, MA, Mad Money, PDC, RGC, RIG, SKS, UNP, WLT

AdvancersAvanir Pharmaceuticals (NasdaqGM:AVNR - News) received an approvable letter and acceptable labeling from the FDA for a new formulation of its antipsychotic drug FazaClo.
Boeing Co. (NYSE:BA - News) net income more than doubled in the fourth quarter, capping a year in which it set a record for airplane orders and setting the stage for higher growth in 2007, the company said.
Bristol-Myers Squibb (NYSE:BMY - News) shares rose following a report in The Financial Times that the company has hired Lehman Bros., Morgan Stanley and Citigroup to help it field possible takeover bids. Earlier in the week, a report surfaced that the company had drawn acquisition interest from French conglomerate Sanofi-Aventis (NYSE:SNY - News).
Catalyst Pharmaceutical Partners (NasdaqGM:CPRX - News) was initiated with a buy rating at Stifel Nicolaus with a $9 price target.
C.H. Robinson Worldwide Inc. (NasdaqGS:CHRW - News) reported fourth-quarter net income of $71.8 million, or 41 cents a share, up from $58.1 million, or 33 cents, a year ago. Quarterly revenue for the trucking company rose to $1.64 billion from $1.58 billion.
CheckFree Corp. (NasdaqGS:CKFR - News) reported a slight profit gain on advances in its core business. For its fiscal second-quarter, CheckFree said net income rose 4% to $35.3 million or 39 cents a share, compared to $33.8 million or 36 cents a share a year ago.
Corus Group Plc (NYSE:CGA - News) shares leapt after India's Tata Steel won a bidding war to acquire the Anglo-Dutch steelmaker for $12.1 billion.
EchoStar Communications (NasdaqGS:DISH - News) was upgraded to overweight from equal-weight at Morgan Stanley. The firm lifted its price target on the shares to $44 from $40.
Estee Lauder (NYSE:EL - News) shot up after the cosmetics giant said its second-quarter profit more than doubled amid robust sales of major lines coupled with cost cutting and a favorably currency exchange.
Frontier Oil (NYSE:FTO - News) was upgraded to neutral from underperform at Credit Suisse.
Harris Corp. (NYSE:HRS - News) said second-quarter net income rose, as revenue gained, to $94 million, or 67 cents a share, from $30 million, or 22 cents a share, during the same period in the prior year. Before items, quarterly per-share income rose to 68 cents from 52 cents in the prior year.
Harris Stratex Networks (NasdaqGM:HSTX - News) was initiated with a buy rating at Merriman Curhan Ford & Co.
Hologic Inc. (NasdaqGS:HOLX - News) reported fiscal first-quarter earnings of $16.1 million, or 30 cents a share, up from a year-ago profit of $5.7 million, or 12 cents a share. Revenue jumped 86% in the latest three months to $163.2 million from $88 million in the same period a year earlier. The Bedford, Mass.-based company attributed the higher earnings to an increase in product sales of its Selenia full-field digital mammography systems.
Ingersoll-Rand (NYSE:IR - News) fourth-quarter earnings fell 24% as sales of its small earthmover Bobcat vehicle slumped due to weaker demand in the North American market, the company's financial results showed Wednesday.
Jones Lang LaSalle Inc. (NYSE:JLL - News) said fourth-quarter net income rose, as revenue gained, to $80.9 million, or $2.37 a share, from $66.9 million, or $1.99 a share, during the same period in the prior year. Analysts were looking for per-share income of $2.26.
Kinetic Concepts (NYSE:KCI - News) was upgraded to buy from hold at Deutsche Bank.
Levitt Corp. (NYSE:LEV - News) agreed to be acquired by BFC Financial Corp. (NYSEArca:BFF - News) for $286 million in stock. In addition, Levitt said preliminary figures show its home building division generated fourth-quarter revenue of $143.6 million, with 426 homes delivered in the quarter at a margin of 19.6%. Backlog at Dec. 31 was 1,248 units with a sales value of $438.2 million. New home orders totaled 204, but were partly offset by 122 cancellations. The company said it has entered into sales contracts to dispose of certain properties and is expected to realize a pre-tax loss of $9.0 million upon disposition, and will write-off $1.4 million in pre-acquisition costs for properties which will not be acquired.
Lone Star Technologies (NYSE:LSS - News) said its fourth-quarter earnings fell to $18.1 million, or 58 cents a share, from $70.9 million, or $2.28 a share, a year earlier, hurt by an income-tax expense. Analysts surveyed by Thomson Financial expected, on average, quarterly earnings of 58 cents a share, before items. The Dallas oilfield pipe and tubing company's revenue for the quarter decreased to $334.8 million from $337.5 million a year ago. Wall Street expected quarterly revenue of $334 million.
New York Times Co. (NYSE:NYT - News) swung to a fourth-quarter loss after an $814 million charge for write-downs, staff-reduction costs and accelerated depreciation.
Omnicell (NasdaqGM:OMCL - News) shares jumped after the company posted fourth-quarter earnings of $3.8 million, or 13 cents a share, up from a year-ago profit of $2.2 million, or 8 cents a share. Revenue rose 26.4% in the latest three months to $42.3 million. The Mountain View, Calif., provider of patient safety technology products said its product backlog ended the quarter at $114.3 million, up 64.2% from the same period a year ago.
O'Reilly Automotive (NasdaqGS:ORLY - News) was upgraded to outperform from neutral at Credit Suisse. The firm lifted its price target on the stock to $38 from $36.
Quicksilver Resources (NYSE:KWK - News) was upgraded to outperform from neutral at Credit Suisse. The firm also boosted its price target on the stock to $47 from $43.
Panera Bread Co. (NasdaqGS:PNRA - News) said same bakery-cafe sales rose 0.8% in January from the same month a year ago. The St. Louis bakery-cafe chain said company-owned same-store sales rose 0.7% while franchise-operated sales were up 0.9%.
ProQuest (NYSE:PQE - News) said Alan Aldworth is leaving its chairman, president and CEO positions, effective immediately. The company named Richard Surratt president and CEO. Surratt had served as the CFO of the Ann Arbor, Mich., publishing company.
RedEnvelope Inc. (NasdaqGM:REDE - News) said third-quarter net income rose, as revenue gained, to $5.31 million, or 56 cents a share, from $4.1 million, or 43 cents a share, during the same period in the prior year. The branded online retailer said quarterly revenue rose to $57 million from $53 million in the prior year.
Red Robin Gourmet Burgers Inc. (NasdaqGS:RRGB - News) said it has signed a non-binding letter of intent to acquire the assets of 17 its franchised restaurants in California for $47.5 million, minus any assumed debt.
Sierra Health Services Inc. (NYSE:SIE - News) reported fourth-quarter net earnings of $39.3 million, or 65 cents a share, compared with $28.3 million, or 44 cents a share, in the same period last year, boosted by higher medical premiums revenue.
Sirf Technology Holdings Inc. (NasdaqGS:SIRF - News) reported fourth-quarter net earnings of $9.1 million, down from $10.23 million in the same period the prior year, mainly due to higher stock-based compensation and acquisition-related contingent payments.
U.S. Concrete (NasdaqGM:RMIX - News) said it sees fourth-quarter revenue of $211 million, compared with its prior view of $195 million to $205 million. The company cited stronger-than-anticipated sales volumes of ready-mixed concrete, partially attributable to relatively mild winter conditions. Analysts polled by Thomson Financial are looking for quarterly revenue of $204 million. U.S. Concrete said it sees a fourth-quarter net loss of 62 cents to 63 cents per share, a view that includes a 70-cent-per-share after-tax goodwill impairment charge associated with its Michigan assets. Excluding the charge, the company expects income for the fourth quarter of 7 to 8 cents per share, compared with its November outlook of 3 to 7 cents. Analysts are looking for per-share income of 5 cents.
Published by Michael Baron at MarketWatch

Labels: AVNR, BA, BFF, BMY, CGA, CHRW, CKFR, CPRX, DISH, EL, FTO, HOLX, HRS, HSTX, IR, JLL, KCI, LEV, LSS, SNY

Shares of Bristol-Myers Squibb jumped to a 52-week high Monday on speculation the company is in talks to be purchased by French drug maker Sanofi-Aventis SA.
Bristol-Myers shares rose $1.65, or 6.3 percent, to $27.86 in morning trading on the New York Stock Exchange. Shares have traded between $20.08 and $27.03 over the past 52 weeks.
Prudential analyst Timothy Anderson said the report comes from a respected publication in France, the weekly La Lettre de l'Expansion. Anderson said the deal would make sense given the companies' current partnership on the blood thinner Plavix, a $5 billion per year drug that is the second best-selling drug in the world.
According to the French article, a deal could possibly close by September.
Both Sanofi-Aventis and Bristol-Myers declined to comment.
Sanofi-Aventis has been considered a favorite for acquiring Bristol-Myers since September 2006, when Bristol-Myers former Chief Executive Peter Dolan was let go, and interim CEO James M. Cornelius took charge. Cornelius' last claim to fame was shepherding the sale of medical device Guidant Corp. to Boston Scientific Corp. Cornelius has repeatedly denied he is interested in a permanent CEO position.
Also, in September, Bristol-Myers Chairman James D. Robinson hinted at the possibility of a sale, saying the company would "deal with any bonafide proposals."
In 2004, the drugmakers Sanofi-Synthelabo and Aventis merged to create the world's third-largest pharmaceutical firm.
American depositary shares of Sanofi-Aventis fell 60 cents to $44.74 on the NYSE.
Published by AP

Labels: BMY, BSX, SNY

Exelixis Inc. and Bristol-Myers Squibb Co. said Monday they will collaborate on therapies for the treatment of cancer. New York-based Bristol-Myers Squibb (NYSE:BMY - News) will pay $60 million upfront to South San Francisco-based Exelixis (NASDAQ:EXEL - News) Exelixis will also receive $20 million for each of up to three different drug candidates selected by Bristol-Myers Squibb. The parties plan to equally share development costs, commercial profits and co-promotion responsibilities in the United States. Exelixis will also receive royalties on product sales outside of the United States. Exelixis is a development-stage biotechnology company focused on novel small molecule therapeutics for the treatment of cancer and other serious diseases.
Source: Bizjournals.com

Labels: BMY, Bristol-Myers Squib Co., EXEL, Exelixis Inc.